Canada - engelsk - Health Canada

la gaspesienne inc., produits sanitaires - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - liquid - 3.5%; 3.5% - benzalkonium chloride 3.5%; alkyl dimethyl ethylbenzyl ammonium chloride 3.5% - disinfectants (for agents used on object)

Canada - engelsk - Health Canada

la gaspesienne inc., produits sanitaires - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - liquid - .8%; .8% - benzalkonium chloride .8%; alkyl dimethyl ethylbenzyl ammonium chloride .8% - disinfectants (for agents used on object)

Andorra - katalansk - CedimCat (Centre d'Informació de Medicaments de Catalunya)

lincomicina - ampollas-inyectable

Andorra - katalansk - CedimCat (Centre d'Informació de Medicaments de Catalunya)

lincomicina - càpsules

Andorra - katalansk - CedimCat (Centre d'Informació de Medicaments de Catalunya)

lincomicina - ampolles-injectable

Tunisia - fransk - Ministère de la Santé, Direction de l'inspection Pharmaceutique

lehning - produits homeopathiques - doses homeopathiques - divers - tous les autres produits therapeutiques - selon chaque médicament homéopathique.

USA - engelsk - NLM (National Library of Medicine)

canus vermont llc - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - zinc oxide 40 g in 142 g - skin protectant. helps treat and prevent diaper rash if condition worsens or does not improve within 7 days.

Den europeiske union - italiensk - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Den europeiske union - spansk - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - leucemia-linfoma linfoblástica de células precursoras - agentes antineoplásicos - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Den europeiske union - spansk - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c, crónica - antivirales para uso sistémico - incivo, en combinación con peginterferón alfa y ribavirina, está indicado para el tratamiento del genotipo 1 de la hepatitis c crónica en pacientes adultos con enfermedad hepática compensada (incluyendo cirrosis):que son el tratamiento ingenuo;que han sido tratados previamente con interferón alfa (pegilado o no pegilado), solos o en combinación con ribavirina, incluyendo con recaída, respondedores parciales y respondedores nulos.